Yes, top line data only. The benefit (as measured by CGI-I) of NTI164 is the same as FDA approved DAYBUE (-0.3) which is good.
The secondary endpoint data will be instructive - if the side effects of the NTI drug are better than DAYBUE then that may be a selling point.
Yes, top line data only. The benefit (as measured by CGI-I) of...
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.4¢ |
Change
0.001(1.37%) |
Mkt cap ! $75.28M | |||
| Open | High | Low | Value | Volume |
| 7.4¢ | 7.5¢ | 7.4¢ | $62.96K | 842.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 209838 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 40000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.4¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.6¢ | 7.4¢ | 264281 | ||
| Last updated 15.56pm 10/05/2024 ? | |||||
| NTI (ASX) Chart |